The Johnson administration hasn't drafted a specific ordinance, but the breadth and cost of the local regulations suggested ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

Like VK2809, VK0214 is also an orally available small molecule that is selected for the beta isoform of the thyroid hormone receptor. X-ALD is a rare and debilitating metabolic disorder that is ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Supporters of gender-affirming care called on the University of Illinois health care system to be clearer and more ...

As a result, patients are unable to efficiently metabolize these acids, and their accumulation is believed to contribute to the onset and progression of X-ALD. Activation of the thyroid hormone ...